Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
NextCure and Simcere Zaiming Announce Strategic Partnership for a Novel Antibody-Drug Conjugate Targeting CDH6
Tuesday, June 17, 2025NextCure Inc a clinicalstage biopharmaceutical company committed to discovering and developing novel firstinclass and bestinclass therapies to treat cancer and Simcere Zaiming an oncologyfocused biopharmaceutical
Ocugen, Inc. Announces U.S. FDA Clearance of Investigational New Drug Amendment to Initiate Phase 2/3 Pivotal Confirmatory Clinical Trial of OCU410ST—Modifier Gene Therapy Candidate for Stargardt Disease
Tuesday, June 17, 2025Ocugen Inc a pioneering biotechnology leader in gene therapies for blindness diseases today announced that the US Food and Drug Administration FDA has cleared the Investigational New Drug IND amendment
Merry Life Launches Global Phase II Trial of TML-6, The First Drug Targeted at Autolysosome pathway for Therapy of Alzheimer's Disease
Friday, June 13, 2025Merry Life Biomedical Company announces the launch of its global Phase II clinical trial for TML a novel oral small molecule drug targeting earlystage Alzheimers disease AD TML combines multiple mechanisms
Biolexis Therapeutics Advances Breakthrough GLP-1 and AMPK Programs into First-in-Human Clinical Trials
Friday, June 13, 2025Biolexis Therapeutics Inca clinicalstage therapeutics company pioneering nextgeneration treatments for metabolic and musclewasting diseases today announced the initiation of Phase I clinical trials for its lead GLP and AMPK small molecule programs Th...
Salipro Biotech and Daewoong Pharmaceutical Announce Collaboration Agreement to Advance Development of Novel Therapeutics
Thursday, June 12, 2025Swedish biotech company Salipro Biotech AB today announced that it has entered into a research collaboration with Daewoong Pharmaceutical Co Ltd Daewoong Pharmaceutical gains access to Salipro Biotechs expertise and Salipro platform
Silo Pharma Secures Biomarker Patent for Novel PTSD Therapeutic SPC-15 as Clinical Trial Nears
Thursday, June 12, 2025Silo Pharma Inc a developmental stage biopharmaceutical company focused on novel therapeutics and drug delivery systems today announced that the US Patent and Trademark Office USPTO had issued a Notice
Zepzelca® (lurbinectedin) and Atezolizumab (Tecentriq®) Combination Granted U.S. FDA Priority Review for First-Line Maintenance Treatment of Extensive-Stage Small Cell Lung Cancer
Wednesday, June 11, 2025Jazz Pharmaceuticals plc today announced the US Food and Drug Administration FDA has accepted the supplemental New Drug Application sNDA for Zepzelca lurbinectedin in combination with atezolizumab Tecentriq
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Wednesday, June 11, 2025Monte Rosa Therapeutics Inc a clinicalstage biotechnology company developing novel molecular glue degrader MGDbased medicines today announced US Food and Drug Administration FDA clearance of an Investigational New Drug
Merck Announces Positive Topline Results From the First Two Phase 3 CORALreef Trials Evaluating Enlicitide Decanoate for the Treatment of Adults With Hyperlipidemia
Tuesday, June 10, 2025Merckknown as MSD outside of the United States and Canada today announced positive topline results from the first two of three Phase clinical trials evaluating the safety and efficacy of enlicitide decanoate an investigational
NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial
Monday, June 09, 2025NewAmsterdam Pharma Company NVa latestage clinical biopharmaceutical company developing oral nonstatin medicines for patients at risk of cardiovascular disease CVD with elevated lowdensity lipoprotein cholesterol
